Novo Nordisk registers a CagriSema trial in painful diabetic neuropathy

Novo Nordisk has registered a clinical trial studying whether CagriSema, an injectable combination of semaglutide and the experimental amylin analog cagrilintide, can ease painful diabetic peripheral neuropathy in people with type 2 diabetes ^[1][2]. The study is a phase 2, randomized, double-blind trial comparing CagriSema to a placebo, with participants rating their pain intensity every week ^[2]. It is officially listed as "Efficacy and Safety of co Administered Cagrilintide and Semaglutide (CagriSema) Once Weekly Versus Placebo in Participants With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy" ^[1].

The trial, identified as NCT06797869, is recruiting 134 adults with type 2 diabetes and overweight or obesity who also have painful diabetic peripheral neuropathy ^[2]. Diatribe's listing estimated the study would run until August 2026 ^[2]. Separately, a TipRanks summary of the trial record notes the study was submitted on January 27, 2025, ran for about 10 months per participant, and was listed as completed with an update posted September 7, 2026 ^[1]. The two sources give slightly different timelines for when data collection wraps up, and neither source reports actual pain-reduction results yet ^[1][2].

CagriSema itself is not yet approved. It combines semaglutide, the active ingredient in Ozempic and Wegovy, with cagrilintide, an amylin analog that has not received regulatory approval ^[2]. In the REDEFINE program studying CagriSema for diabetes and obesity, participants reduced their A1C by an average of 2.2 percentage points and lost almost 16% of their body weight over 32 weeks, with time-in-range blood sugar control improving by 43% compared with cagrilintide alone ^[2]. Those results relate to glucose control and weight, not nerve pain, which is the focus of this newly registered study ^[1][2].

Why it matters for patients

Painful diabetic peripheral neuropathy is a nerve complication of long-term diabetes that current diabetes medications do not treat well ^[1]. If CagriSema were shown to reduce pain scores in this population, it could represent a new use for an incretin-based drug beyond blood sugar and weight control. But this is a phase 2 study, an early stage of testing, and it uses a placebo comparison with weekly self-reported pain ratings rather than a hard clinical outcome like nerve damage reversal ^[1][2].

Patients living with diabetic nerve pain today should not expect this trial to change their treatment options soon. CagriSema is not approved for any use in the United States, and this study is testing an additional, separate indication on top of the diabetes and obesity uses already being evaluated in the REDEFINE program ^[2]. Neither source in this record reports whether the nerve pain trial met its goals, and no results have been published ^[1][2].

For people already on GLP-1 or amylin-based therapies, or those considering them, this development signals that manufacturers are looking to expand these drugs' uses into diabetes-related complications, not just glucose and weight ^[1]. That pattern could eventually widen who these medications are prescribed for, but only if trials like this one produce clear, published evidence.

What happens next

The trial record reviewed here shows a status of "completed" as of an update dated September 7, 2026, meaning data collection for participants has apparently ended ^[1]. However, no pain-reduction results, safety data, or peer-reviewed publication are referenced in either source ^[1][2]. Until Novo Nordisk or investigators release detailed findings, it is not yet known whether CagriSema reduced weekly pain intensity scores compared with placebo, or what side effects were observed in this population.